Clinical Pharmacology Clinical Research Clinical Trials 
Drug Target Review
APRIL 7, 2025
A surrogate endpoint is a marker used in clinical trials as a substitute for a direct clinical outcome. Diagnostic biomarkers typically confirm or establish a diagnosis and are often used in selecting patient populations for clinical trials. Clinical Pharmacology and Therapeutics. Rodrigues AD.
Drug Target Review
MAY 7, 2024
AI holds the potential to revolutionise different aspects of healthcare, particularly in the realm of clinical trials. By leveraging AI technologies, we could create a more accessible and equitable approach to clinical trials, breaking down barriers to participation and ensuring diverse representation among participants.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Alta Sciences
JANUARY 23, 2024
“James’ proven leadership skills, and deep knowledge of all phases of clinical research, will be invaluable in delivering expert guidance for our clients along their early-phase clinical journey,” said Ingrid Holmes, Vice President, Clinical Operations, Altasciences.
Alta Sciences
DECEMBER 14, 2023
Adherence to harmonized pharmacy-specific SOPs based on cGMP principles at our three clinical pharmacology units. Clinical Supply Manufacturing Integration with our manufacturing team, ensuring flexibility and adaptability to meet the evolving needs of your studies throughout your drug development program or study.
Alta Sciences
JULY 31, 2024
How Improving Diversity Can Benefit Clinical Trials pmjackson Wed, 07/31/2024 - 19:19 In July 2024, the U.S. Food and Drug Administration (FDA) published a draft guidance to ensure greater diversity in clinical trials, which is expected to become a final guidance by June 2025.
The Premier Consulting Blog
JUNE 18, 2023
One exciting application of these technologies is the use of in silico trials in the development of novel therapies for rare diseases. However, with rare diseases there may be no available treatments that could serve as SoC or active control in a clinical trial and assigning patients to placebo may be unethical.
Alta Sciences
AUGUST 28, 2023
We wish the team at Ischemix continued success on the next Phase of clinical research.” Julie-Ann Cabana Altasciences +1 514 601-9763 jcabana@altasciences.com Date of publication August 30, 2023 Weight 1 Tags Clinical Trials Altasciences helps sponsors get better drugs to the people who need them, faster.
Expert insights. Personalized for you.
69 
Let's personalize your content